{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T12:18:42Z","timestamp":1788178722019,"version":"build-2803163510"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,31]]},"DOI":"10.7759\/cureus.115495","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:55:04Z","timestamp":1788177304000},"source":"Crossref","is-referenced-by-count":0,"title":["Ibrutinib as the Unifying Culprit: A Case Report of Multisystem Complications in an Elderly Patient With Low-Grade B-Cell Lymphoproliferative Disorder"],"prefix":"10.7759","author":[{"given":"Khalid","family":"Ghalib","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Elnour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Eltigani Hassan Mahgoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro","family":"Arregui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000725","article-title":"How I treat Waldenstr\u00f6m macroglobulinemia","volume":"134","author":"Dimopoulos MA","year":"2019","unstructured":"Dimopoulos MA, Kastritis E. How I treat Waldenstr\u00f6m macroglobulinemia. Blood. 2019, 134:2022-35. 10.1182\/blood.2019000725","journal-title":"Blood"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.656103","article-title":"Waldenstr\u00f6m macroglobulinemia: a Surveillance, Epidemiology, and End Results Database review from 1988 to 2005","volume":"53","author":"Sekhar J","year":"2012","unstructured":"Sekhar J, Sanfilippo K, Zhang Q, Trinkaus K, Vij R, Morgensztern D. Waldenstr\u00f6m macroglobulinemia: a Surveillance, Epidemiology, and End Results Database review from 1988 to 2005. Leuk Lymphoma. 2012, 53:1625-6. 10.3109\/10428194.2012.656103","journal-title":"Leuk Lymphoma"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27666","article-title":"Waldenstr\u00f6m macroglobulinemia: 2025 update on diagnosis, risk stratification, and management","volume":"100","author":"Gertz MA","year":"2025","unstructured":"Gertz MA. Waldenstr\u00f6m macroglobulinemia: 2025 update on diagnosis, risk stratification, and management. Am J Hematol. 2025, 100:1061-73. 10.1002\/ajh.27666","journal-title":"Am J Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P somatic mutation in Waldenstr\u00f6m's macroglobulinemia","volume":"367","author":"Treon SP","year":"2012","unstructured":"Treon SP, Xu L, Yang G, et al.. MYD88 L265P somatic mutation in Waldenstr\u00f6m's macroglobulinemia. N Engl J Med. 2012, 367:826-33. 10.1056\/NEJMoa1200710","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia","volume":"378","author":"Dimopoulos MA","year":"2018","unstructured":"Dimopoulos MA, Tedeschi A, Trotman J, et al.. Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m\u2019s macroglobulinemia. N Engl J Med. 2018, 378:2399-410. 10.1056\/NEJMoa1802917","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.316","article-title":"Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib","volume":"31","author":"Kazianka L","year":"2017","unstructured":"Kazianka L, Drucker C, Skrabs C, et al.. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib. Leukemia. 2017, 31:1117-22. 10.1038\/leu.2016.316","journal-title":"Leukemia"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-604272","article-title":"Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling","volume":"124","author":"McMullen JR","year":"2014","unstructured":"McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS. Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling. Blood. 2014, 124:3829-30. 10.1182\/blood-2014-10-604272","journal-title":"Blood"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211228","article-title":"Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis","volume":"14","author":"Caldeira D","year":"2019","unstructured":"Caldeira D, Alves D, Costa J, Ferreira JJ, Pinto FJ. Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis. PLoS One. 2019, 14:e0211228. 10.1371\/journal.pone.0211228","journal-title":"PLoS One"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13098","article-title":"Infection with ibrutinib in patients with chronic lymphocytic leukemia: how strong is the association?","volume":"101","author":"Ball S","year":"2018","unstructured":"Ball S, Vutthikraivit W, Maiti A, Short NJ. Infection with ibrutinib in patients with chronic lymphocytic leukemia: how strong is the association?. Eur J Haematol. 2018, 101:418-20. 10.1111\/ejh.13098","journal-title":"Eur J Haematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2022.2038372","article-title":"Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma","volume":"63","author":"Siddiqi T","year":"2022","unstructured":"Siddiqi T, Coutre S, McKinney M, et al.. Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma. Leuk Lymphoma. 2022, 63:1580-8. 10.1080\/10428194.2022.2038372","journal-title":"Leuk Lymphoma"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219856422","article-title":"Ibrutinib-associated sever skin toxicity: a case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - case report and literature review","volume":"26","author":"Ghasoub R","year":"2020","unstructured":"Ghasoub R, Albattah A, Elazzazy S, Alokka R, Nemir A, Alhijji I, Taha R. Ibrutinib-associated sever skin toxicity: a case of multiple inflamed skin lesions and cellulitis in a 68-year-old male patient with relapsed chronic lymphocytic leukemia - case report and literature review. J Oncol Pharm Pract. 2020, 26:487-91. 10.1177\/1078155219856422","journal-title":"J Oncol Pharm Pract"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.galenos.2020.2020.0120","article-title":"Ibrutinib-induced skin rash","volume":"38","author":"Kirar S","year":"2021","unstructured":"Kirar S, Gogia A, Gupta R, Mallick S. Ibrutinib-induced skin rash. Turk J Haematol. 2021, 38:81-3. 10.4274\/tjh.galenos.2020.2020.0120","journal-title":"Turk J Haematol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13192","article-title":"Sj\u00f6gren syndrome-associated lymphomas: an update on pathogenesis and management","volume":"168","author":"Nocturne G","year":"2015","unstructured":"Nocturne G, Mariette X. Sj\u00f6gren syndrome-associated lymphomas: an update on pathogenesis and management. Br J Haematol. 2015, 168:317-27. 10.1111\/bjh.13192","journal-title":"Br J Haematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.20658","article-title":"Initial immunoglobulin M \u2018flare\u2019 after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group study","volume":"101","author":"Ghobrial IM","year":"2004","unstructured":"Ghobrial IM, Fonseca R, Greipp PR, Blood E, Rue M, Vesole DH, Gertz MA. Initial immunoglobulin M \u2018flare\u2019 after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group study. Cancer. 2004, 101:2593-8. 10.1002\/cncr.20658","journal-title":"Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2017.1394554","article-title":"Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia","volume":"19","author":"Mato AR","year":"2018","unstructured":"Mato AR, Clasen S, Pickens P, et al.. Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia. Cancer Biol Ther. 2018, 19:1-2. 10.1080\/15384047.2017.1394554","journal-title":"Cancer Biol Ther"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/4282486","article-title":"Ibrutinib-associated cardiac tamponade with concurrent antiplatelet therapy","volume":"2020","author":"Miatech JL","year":"2020","unstructured":"Miatech JL, Hughes JH, McCarty DK, Stagg MP. Ibrutinib-associated cardiac tamponade with concurrent antiplatelet therapy. Case Rep Hematol. 2020, 2020:4282486. 10.1155\/2020\/4282486","journal-title":"Case Rep Hematol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.147900","article-title":"Ibrutinib for relapsed\/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients","volume":"101","author":"UK CLL Forum","year":"2016","unstructured":"UK CLL Forum. Ibrutinib for relapsed\/refractory chronic lymphocytic leukemia: a UK and Ireland analysis of outcomes in 315 patients. Haematologica. 2016, 101:1563-72. 10.3324\/haematol.2016.147900","journal-title":"Haematologica"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/521360-ibrutinib-as-the-unifying-culprit-a-case-report-of-multisystem-complications-in-an-elderly-patient-with-low-grade-b-cell-lymphoproliferative-disorder","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:55:05Z","timestamp":1788177305000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/521360-ibrutinib-as-the-unifying-culprit-a-case-report-of-multisystem-complications-in-an-elderly-patient-with-low-grade-b-cell-lymphoproliferative-disorder"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.115495","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}